Blueprint Medicines

What Blueprint Medicines does

Blueprint Medicines, a Sanofi company since June 2025, is a biopharmaceutical firm headquartered in Cambridge, Massachusetts that develops precision kinase-targeted therapies for genomically defined cancers and rare allergic/inflammatory diseases. The company's core technology is a proprietary kinase-targeted drug discovery platform designed to produce highly selective small molecules that address the underlying biology of diseases driven by specific kinase mutations, particularly KIT and PDGFRA. Its approved product AYVAKIT (avapritinib) is a KIT and PDGFRA inhibitor approved in the U.S. and Europe for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring PDGFRA exon 18 mutations including D842V. The pipeline includes elenestinib (BLU-263), a KIT inhibitor in development for systemic mastocytosis, and BLU-808, a planned candidate for chronic urticaria and other mast cell-mediated diseases.

The business model is commercial-stage specialty biopharma: revenue is generated primarily through global product sales of AYVAKIT, distributed via specialty pharmacy channels with a dedicated patient support program (YourBlueprint) providing access, co-pay, and adherence support. The go-to-market motion relies on specialty field sales teams and medical science liaisons targeting hospitals, academic medical centers, and specialty pharmacies, supplemented by medical conference presence (AAAAI, ASH, EAACI), digital properties, and direct medical-information channels. Post-acquisition, Blueprint's commercial reach is amplified by Sanofi's global specialty/immunology infrastructure, while its products are made available outside the U.S. and China through marketing authorizations and a Named Patient Program.

Customer segments are organized by rare disease indication rather than enterprise buyer: indolent systemic mastocytosis patients (primary), advanced systemic mastocytosis patients (aggressive SM, SM-AHN, mast cell leukemia), and GIST patients with PDGFRA exon 18 mutations. Payer mix is fragmented across commercial insurers and government programs typical for high-cost rare disease therapies, with pricing disclosed under state transparency requirements. The company was acquired by Sanofi for approximately $9.5 billion ($129 per share plus milestone payments), validating the franchise value of its kinase precision medicine platform.

Name

Blueprint Medicines

Legal name

Blueprint Medicines Corporation

Website

https://blueprintmedicines.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Blueprint Medicines, a Sanofi company, develops precision kinase-targeted therapies for systemic mastocytosis, PDGFRA-mutant GIST, and other rare allergic/inflammatory and oncology diseases. Lead product AYVAKIT (avapritinib) is approved in the U.S. and Europe.

Ownership category

akta.pro rank

Product category

Precision Oncology Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Mast Cell Disorders Specialty Care (HLAKAAAH)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Precision oncology therapeutics
• Kinase inhibitor drugs
• Systemic mastocytosis treatment
• Targeted cancer therapy
• Rare disease biopharmaceuticals

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Product Sales (AYVAKIT): Revenue generated from global sales of AYVAKIT (avapritinib) for approved indications in indolent systemic mastocytosis, advanced systemic mastocytosis, and GIST. As a Sanofi company post-acquisition, product revenues contribute to Sanofi's portfolio.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Blueprint Medicines develops and commercializes precision kinase-targeted therapies, most notably AYVAKIT (avapritinib), a KIT and PDGFRA inhibitor approved in the U.S. and Europe for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic GIST harboring PDGFRA exon 18 mutations. The pipeline includes elenestinib (BLU-263) in development for systemic mastocytosis and BLU-808 for chronic urticaria and other mast cell-mediated diseases.

Product overview

Blueprint Medicines is a biopharmaceutical company that develops precision-targeted therapies for systemic mastocytosis and other allergic/inflammatory diseases and cancer. The company's approved product AYVAKIT (avapritinib) addresses KIT-mediated diseases including indolent and advanced systemic mastocytosis and GIST. The pipeline includes elenestinib (BLU-263) for systemic mastocytosis indications and BLU-808 for chronic urticaria and mast cell-mediated diseases. Following Sanofi's acquisition in 2025, the company operates as part of the Sanofi portfolio while maintaining its focused drug development approach.

Differentiator

Problem solved

Functional benefit

Brands

• AYVAKIT: Avapritinib - approved drug for indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutation
• YourBlueprint

Products and services

• AYVAKIT (avapritinib) AYVAKIT is an approved precision therapy targeting KIT and PDGFRA mutations, indicated for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic GIST harboring PDGFRA exon 18 mutations including the D842V mutation.
• Elenestinib (BLU-263) Elenestinib is a development-stage KIT inhibitor being studied for treatment of indolent systemic mastocytosis and advanced systemic mastocytosis.
• BLU-808 BLU-808 is a planned development program targeting chronic spontaneous and inducible urticaria and additional common mast cell-mediated diseases.

Quantifiable outcome

• 46.5-month median follow-up with sustained symptom control and quality of life improvements in ISM patients
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SanofiflagshipStrategic or Co-development Partner · 1 June 2025Sanofi acquired Blueprint Medicines Corporation for approximately $9.5 billion (up to $9.5B with milestone payments), expanding Sanofi's rare immunological disease portfolio and pipeline. The acquisition included marketed drugs AYVAKIT (avapritinib) and early-stage candidates. Blueprint now operates as a Sanofi company. Deal closed Q3 2025.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Deciphera Pharmaceuticals: Develops Qinlock (ripretinib) for GIST, making it a direct competitor to AYVAKIT in kinase-driven GIST treatment with overlapping prescriber audiences.
• Exelixis: Markets Cabometyx (cabozantinib) for advanced GIST after prior therapy, overlapping with Blueprint's PDGFRA-mutant GIST positioning and kinase-inhibitor oncology expertise.
• Novartis: Markets Rydapt (midostaurin), the other approved multikinase inhibitor for advanced systemic mastocytosis, making it Blueprint's most direct competitor in the KIT-driven SM market.

Emerging players

• Allakos: Focused on mast cell and eosinophil-driven diseases, with adjacent programs in chronic urticaria and other mast cell-mediated conditions targeted by Blueprint's BLU-808.
• Cogent Biosciences: Developing bezuclastinib for systemic mastocytosis and GIST, positioning it as the most advanced late-stage challenger to Blueprint's AYVAKIT franchise in both ISM and advanced SM.

Broad incumbents

• Sanofi: Acquired Blueprint Medicines in 2025 and operates it as a wholly-owned subsidiary; Sanofi is also a broad incumbent in immunology, rare disease, and oncology with overlapping kinase and inflammatory portfolios.
• AbbVie: Large immunology and oncology incumbent with deep rare disease commercial infrastructure; pursues precision oncology and allergic/inflammatory disease programs adjacent to Blueprint's focus areas.
• AstraZeneca: Oncology and rare disease major with kinase inhibitor expertise (e.g., Tagrisso) and growing immunology footprint, making it both a potential competitor and strategic acquirer for precision rare disease assets.
• Bristol-Myers Squibb: Major biopharmaceutical company with deep oncology and immunology pipelines, including kinase inhibitors and rare hematology assets adjacent to Blueprint's SM and GIST franchises.
• Pfizer: Diversified biopharmaceutical incumbent with precision oncology, rare disease, and immunology capabilities that overlap with Blueprint's kinase-targeted rare disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/blueprintmeds
• LinkedInlinkedin.com/company/blueprint-medicines

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds10 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blueprint Medicines